| ArriVent BioPharma Reports First Quarter 2025 Financial Results |
Completed enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutations Planned update for development of firmonertinib in first-line NSCLC PACC mutations in Q2 2025 First IND for ARR-217 (MRG007), an antibody drug conjugate (ADC) targeting CDH17, submitted in China Cash, cash equivalents and marketable securities of $205.5 million as of March 31, 2025 NEWTOWN SQUARE, Pa., May 12, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2025, and highlighted recent Company progress. |
globenewswire.com |
2025-05-12 12:00:00 |
Czytaj oryginał (ang.) |
| ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors |
NEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Merdad Parsey, M.D. |
globenewswire.com |
2025-04-28 12:00:00 |
Czytaj oryginał (ang.) |
| ArriVent BioPharma Reports Full Year 2024 Financial Results |
NEWTOWN SQUARE, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the year ended December 31, 2024, and highlighted recent Company progress. |
globenewswire.com |
2025-03-03 09:00:00 |
Czytaj oryginał (ang.) |
| ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers |
NEWTOWN SQUARE, Pa. and SHANGHAI, Jan. 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP) a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that it has entered into an exclusive license agreement with Lepu Biopharma Co., Ltd (Stock Code: 02157.HK) for MRG007, an antibody-drug conjugate (ADC) that can target several gastrointestinal (GI) cancers. Under the terms of the agreement, ArriVent obtains the exclusive rights to develop and commercialize MRG007 worldwide outside of Greater China which includes mainland China, Hong Kong, Macau and Taiwan. |
globenewswire.com |
2025-01-21 21:00:00 |
Czytaj oryginał (ang.) |
| Discover the 3 Best-Performing Biotech IPO Stocks of 2024 |
Biotech and pharmaceutical companies are well known for raising capital through initial public offerings, or IPOs. Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies. |
marketbeat.com |
2024-11-06 10:30:04 |
Czytaj oryginał (ang.) |
| ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer |
81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not yet reached at time of analysis ArriVent to host virtual webinar on these interim analyses of Phase 1b data for firmonertinib in EGFR PACC mutant NSCLC on September 9, 2024 at 4:30 pm ET NEWTOWN SQUARE, Pa., Sept. 09, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced positive proof-of-concept randomized global Phase 1b FURTHER interim data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations at a Presidential Symposium Presentation at the IASCLC 2024 annual World Conference on Lung Cancer (WCLC), in San Diego, California. |
globenewswire.com |
2024-09-09 16:05:00 |
Czytaj oryginał (ang.) |
| Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 27.26%: Read This Before Placing a Bet |
The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 27.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. |
zacks.com |
2024-08-19 14:55:47 |
Czytaj oryginał (ang.) |
| Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma |
HAYWARD, Calif.--(BUSINESS WIRE)-- #biotechnology--Aarvik Therapeutics is pleased to announce that ArriVent BioPharma, Inc. has exercised the option to exclusively license the collaboration program. |
businesswire.com |
2024-08-15 11:01:00 |
Czytaj oryginał (ang.) |
| ArriVent BioPharma Reports Second Quarter 2024 Financial Results |
Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World Conference on Lung Cancer (WCLC) |
globenewswire.com |
2024-08-14 20:01:00 |
Czytaj oryginał (ang.) |
| ArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung Cancer |
First-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session |
globenewswire.com |
2024-08-12 12:00:00 |
Czytaj oryginał (ang.) |
| ArriVent Announces a Multi-Target ADC Collaboration with Alphamab |
Collaboration will leverage Alphamab's antibody drug conjugate (“ADC”) research and discovery platform and ArriVent's global development and commercialization expertise |
globenewswire.com |
2024-06-05 11:00:00 |
Czytaj oryginał (ang.) |
| ArriVent Appoints John Hohneker, M.D., to its Board of Directors |
NEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of John Hohneker, M.D. to its Board of Directors. Dr. Hohneker brings over 30 years of experience in biopharmaceutical leadership and drug development, and currently serves on the Boards of public companies Carisma Therapeutics, Inc. and Curis, Inc., and private companies Sonata Therapeutics and Trishula Therapeutics. |
globenewswire.com |
2024-05-16 20:05:00 |
Czytaj oryginał (ang.) |
| ArriVent BioPharma Reports First Quarter 2024 Financial Results |
NEWTOWN SQUARE, Pa., May 08, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the first quarter ended March 31, 2024, and highlighted recent Company progress. |
globenewswire.com |
2024-05-08 12:00:00 |
Czytaj oryginał (ang.) |
| ArriVent Appoints Kristine Peterson to its Board of Directors |
NEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the appointment of Kristine Peterson to its Board of Directors. Ms. Peterson brings over 30 years of biopharmaceutical leadership experience, and currently serves on the Boards of public companies Immunocore, Inc. and Enanta Pharmaceuticals. |
globenewswire.com |
2024-04-22 20:05:00 |
Czytaj oryginał (ang.) |
| InnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor Furmonertinib |
BEIJING, China--(BUSINESS WIRE)--InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor, ICP-189, with ArriVent's furmonertinib, a highly brain-penetrant, broadly active mutation-selective EGFR (epidermal growth factor receptor) inhibitor in patients with a. |
businesswire.com |
2024-03-28 22:30:00 |
Czytaj oryginał (ang.) |
| ArriVent BioPharma Reports Full Year 2023 Financial Results |
NEWTOWN SQUARE, Pa., March 28, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (“Company” or “ArriVent”) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the full year ended December 31, 2023, and highlighted recent company progress. |
globenewswire.com |
2024-03-28 18:05:00 |
Czytaj oryginał (ang.) |
| Insider Buying at These Biotechs Is Huge |
As January wound to a close, the most notable insider purchases were in biopharma companies, particularly those with initial or secondary offerings of stock. |
247wallst.com |
2024-02-05 14:09:11 |
Czytaj oryginał (ang.) |
| ArriVent Wows Investors With Promising China-Developed Lung Cancer Treatment |
ArriVent raised $150 million in an upsized IPO, marking one of the strongest performances for a China-linked IPO in New York over the last two years. The company has licensed global rights, excluding Greater China, to furmonertinib, a highly targeted drug used to treat non-small-cell lung cancer. |
seekingalpha.com |
2024-01-29 20:15:00 |
Czytaj oryginał (ang.) |